What is Mecasermin?

The short answer

Mecasermin is a protein. In the US, you need a prescription to get Mecasermin.

2 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialUpdated October 7, 2026AI use

Get updates on Mecasermin

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: Mecasermin (1 selected) · edit

Peptides you're interested inMecasermin

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on Mecasermin

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: Recombinant IGF-1 (protein)
Also known as: increlex, igf-1, rhigf-1
How it works: Replaces IGF-1 in severe primary IGF-1 deficiency.

Regulatory status

FDA-approved (Rx) How we label status

As of October 4, 2026, Mecasermin is an FDA-approved prescription drug for severe primary IGF-1 deficiency in children.

See Mecasermin in the Index →

Federal (FDA): Approved Rx (Increlex BLA021839, 2005)
503A compounding: Approved-drug component (not in any 503A category) (as of May 14, 2026)
WADA 2026: S2.3

References

Sources as of October 4, 2026